Search

Language:中文ENGLISH

E-mail: sales_liu@bonabio.cn

Whatsapp: +86-18963064736

Wechat: +86-18963064736

QQ: 2862752579

TM: Bonabio

Address: Block D, Century Fortune Center, High-tech Zone, Jinan City, Shandong Province, China

Copyright(c)2020  ©  Shandong Bona Biological Technology Group Co., Ltd. 鲁ICP备12034225号-5

CONTACT US

PRODUCTS

ABOUT US

MESSAGES

NEWS

NEWS

BONA BIOTECHNOLOGY GROUP

National Biomedical Industry Base

Classification:
Industry News
Author:
Source:
Release time:
2020/10/27 18:30
Page view
[Abstract]:

In recent years, the National Development and Reform Commission has taken a series of measures to vigorously promote the agglomeration development of the biological industry. Currently, 22 national bio-industry bases have been approved.
     In order to promote the agglomeration development of the biological industry, guide social resources to focus on key areas, promote the healthy and rapid development of my country’s biological industry, promote the formation of distinctive biological industries in various places, and avoid redundant construction and dispersion of resources. In accordance with the principle of “planning overall, giving full play to advantages, categorized guidance, and steadily advancing”, during the “11th Five-Year Plan” period, the National Development and Reform Commission will select regions with a good industrial foundation, strong innovation capabilities, high marketization, and strong openness to build the country in batches Biological industry base and national high-tech industrial base. Up to now, 12 national bio-industry bases have been identified including Shijiazhuang, Shenzhen, Changsha, Beijing, Shanghai, Guangzhou, Wuhan, Kunming, Qingdao, Chengdu, Chongqing, etc., as well as Xi’an, Tianjin, Taizhou, Tonghua, Dezhou, Zhengzhou, Nanning, Harbin, Hangzhou, Nanchang and other 10 national high-tech industrial bases in the biological industry sector.
     Under the guidance of the state and local promotion, the agglomeration development of the bio-industry has been greatly guided and promoted, and three comprehensive bio-industry bases in the Yangtze River Delta, the Pearl River Delta and the Beijing-Tianjin-Hebei region have been gradually cultivated throughout the country, as well as the Northeast and China The spatial layout of several specialized biological industry bases in the western region has promoted the concentration of biological enterprises, capital, technology, and talents in advantageous areas, and accelerated the development of agglomeration and characteristic of the biological industry, and the agglomeration effect has initially appeared. In 2007, the 12 national biological industry bases achieved a total industrial output value of 314.5 billion yuan, an increase of 21% year-on-year, accounting for nearly half of the national biological industry. In order to promote the agglomeration and development of the biological industry, various localities have introduced a series of supporting preferential policies through sound institutions and mobilization of resources, laying a good foundation for vigorously developing a batch of biological industry bases. The construction of the base has played a major role in creating an environment for the development of the bio-industry, gathering domestic and foreign bio-industry resources on a large scale, optimizing the structure and layout of the bio-industry, forming an internationally competitive bio-industry growth pole as soon as possible, radiating and driving the rapid development of my country's bio-industry .

The first batch of national bio-industry bases (June 2005)
Shijiazhuang Base
     The characteristic base relies on the Shijiazhuang Economic and Technological Development Zone. The core area has a planned area of ​​17 square kilometers. It has more than 40 related biological enterprises such as Huayao, CSPC and Siyao, with a total investment of over 10 billion yuan. There are currently 178 key construction projects divided into four categories: one is the chemical pharmaceutical field; the second is the biopharmaceutical field; the third is the modern Chinese medicine field; the fourth is the public supporting field. In 2006, it achieved sales revenue of 28 billion yuan.
     Construction goal By 2012, the annual output value of the biological industry will reach 48.5 billion yuan.
Changchun Base
     The characteristic base will be composed of three modules: the core area of ​​the pharmaceutical industry is located in the Changchun High-tech Industrial Development Zone, the core area of ​​the bio-industry is located in the Changchun Economic and Technological Development Zone, and the core area of ​​biological agriculture is located in the Jingyuetan Tourism Economic Development Zone in the east of the city. The area is 13.4 square kilometers.
     It is currently the largest vaccine and gene medicine production base in Asia. In the field of biological manufacturing, Changchun Dacheng Industrial Group is the world's largest producer of lysine. In the field of bioenergy, the ethanol gasoline project is the only pilot city in the country; Dacheng Group's investment of 10 billion yuan in annual production of 1 million tons of chemical alcohol projects is one of the largest chemical alcohol projects in the country.
     Construction goal By 2010, the annual output value of the biological industry will reach 70 to 100 billion yuan.
Shenzhen Base
     The characteristic core area is Shenzhen High-tech Industrial Park, and the expansion area is the two areas of Guangming and Nan'ao. The industrial land is nearly 3 square kilometers. In 2006, there were 123 companies with sales revenue exceeding 10 million yuan, of which 36 companies had an output value of 100 million to 1 billion yuan.
     Through the establishment of a complete bio-industry technology support platform and industrial supporting system, Shenzhen has become the domestically market-oriented and fully functional achievement transformation base, the most competitive innovative drug research and development and industrialization base, and the most technologically advanced medical device Product production base.
     Construction goal By 2010, the annual output value of the biological industry will reach 70 billion to 100 billion yuan.

The second batch of national bio-industry bases (October 2006)
Changsha Base
     The feature is the first national bio-industry base in the central region of my country, with "one park and five zones" in the base. The base has formed 11 pharmaceutical industry clusters. Among them, Chinese medicine detoxification drugs rank first in the country, biological vaccines and antibiotic preparations rank first in Central and South China, weight-loss health products rank third in the country, and standardized Chinese medicine extracts rank second in the country. In 2007, the base achieved a total industrial output value of 7.063 billion yuan.
     Construction goal By 2015, the annual output value of the biological industry will reach 80 billion yuan.
Guangzhou Base
     The characteristic base plan is composed of two core areas, an expansion area and a radiation area. The overall planning area is about 13 square kilometers. Focus on the development of four major biomedicine fields, including genetic engineering drugs, modern Chinese medicines, chemical synthesis innovative drugs, and marine drugs, and focus on the development of bio-agriculture, and promote the development of the bio-service industry (biotechnology research and development, etc.). There are more than 300 biological enterprises of various types, of which more than 70 are large-scale, and 19 have an annual output value of over 100 million yuan. Guangzhou Pharmaceutical Group ranks in the forefront of the national pharmaceutical industry in scale and efficiency. In 2007, Guangzhou's bio-industry completed a total output value of approximately 35.8 billion yuan, accounting for 12.5% ​​of the city's high-tech product output value.
     Construction goal By 2010, the annual output value of the biological industry will reach an industrial scale of 100 billion yuan.
Shanghai Base
     Features The spatial layout is based on the "1+4" structure. "1" means a core area, which is the Zhangjiang High-tech Park; "4" means four expansion areas. Focus on the development of new products in the fields of genetic engineering drugs, modern Chinese medicines, chemical synthesis innovative drugs, biomedical engineering, etc., actively promote the implementation of major projects, promote the integration of large-scale biological enterprise groups and the development of small and medium-sized enterprises, and gradually form a complete innovation system and distinctive industrial characteristics , A national comprehensive bio-industry research and development, production and export base with a reasonable layout. In 2007, the total output value of Shanghai's pharmaceutical industry was 38.896 billion yuan. It has maintained an average annual growth rate of more than 17% for 7 consecutive years and has become one of Shanghai's major emerging industries.
     Construction goal: By 2010, the base's high-tech industry independent intellectual property rights will have a 30% ownership rate, cultivate a number of large-scale high-tech enterprises with annual sales revenue of over 10 billion yuan, and develop a number of highly competitive high-tech industry brands.
Beijing Base
     The characteristic base consists of three core areas: Zhongguancun Life Science Park, Beijing Economic and Technological Development Zone and Zhongguancun Daxing Biomedical Base. As a national political center, education center, technology center, media center, and central enterprise headquarters center, Beijing has a large amount of information resources. In addition, talents and R&D institutions are intensive. Fortune 500 companies have set up more than 150 branches in Zhongguancun, including more than 70 R&D institutions. Large domestic companies have also set up R&D institutions in Beijing. The base focuses on the development of genetic engineering drugs and biomedical engineering products.
     Construction goal By 2010, the added value of Beijing’s high-tech industry will account for more than 22% of the region’s GDP, and the city’s R&D investment will exceed 6% of the region’s GDP, initially building an innovative city; by 2020, enter the world’s innovative city The first column.

The third batch of national biological industry bases (June 2007)
Qingdao Base
     Featured industrial technologies are mainly concentrated in the fields of biomedicine, agricultural biotechnology, industrial biotechnology and traditional biotechnology. In 2007, the base achieved a total industrial output value of 8.64 billion yuan, a year-on-year increase of 32.7%.
     Construction goals: By 2010, there will be about 300 marine biological enterprises, and the annual output value of the biological industry will reach 22 billion yuan; by 2015, there will be about 500 marine biological enterprises, and the annual output value of the biological industry will reach 60 billion yuan; by 2020, the biological industry The annual output value will reach 120 billion yuan.
Wuhan Base
     The characteristic core area includes four characteristic industrial parks, Guannan Biopharmaceutical Park in East Lake Development Zone, Jiangxia Modern Chinese Medicine Park, Gedian Chemical Synthetic Innovative Medicine Park, and Nanhu Biological Agriculture Park, covering an area of ​​30 square kilometers. In 2007, the output value of the biological industry was 8.112 billion yuan, an increase of 6.3% over the same period last year.
     It has obvious advantages in biological preparations, diagnostic reagents and chip products, and diagnosis and treatment centers. Biological vaccines rank fifth in the country.
     Construction goals: By 2012, the annual output value of the biological industry will reach 30 billion to 35 billion yuan; by 2015, strive to build Wuhan into the largest national biological industry base in central China.
Chengdu Base
     The characteristic core area is Chengdu High-tech Zone. In 2007, the total output value of biomedicine and bio-agriculture was 42.1 billion yuan, including 19.3 billion yuan for biomedicine and 22.8 billion yuan for bio-agriculture.
     The first is to vigorously develop biomedicine, including modern Chinese medicine, innovative drugs, biomedical engineering, and biomedical services; the second is to accelerate the development of resource-technology-led bio-agriculture and bio-energy.
     Construction goals: By 2010, the annual output value of the biological industry will reach 50 billion yuan; by 2020, the annual output value of the biological industry will reach 120 billion yuan.
Kunming Base
     The characteristic base focuses on the development of bio-agricultural industries based on high-quality seed industries, major transnational animal diseases, and safety evaluation and detection products for the invasion of harmful biological species; biological pesticides and biological fertilizers.
     Construction goal: By 2010, the annual output value of the biological industry will reach 50 billion yuan; by 2020, the annual output value of the biological industry will reach 120 billion yuan.
Chongqing Base
     Features focus on the development of six major industrial areas: biomedical engineering, standardized planting of Chinese medicinal materials and modern pharmaceuticals, veterinary drugs and green agricultural biological products, characteristic biological breeding, biomass engineering, and biotechnology service industries.
     Construction goal: By 2012, the annual output value of the biological industry will reach 100 billion yuan; by 2020, the annual output value of the industry will reach 200 billion yuan.
The fourth batch of national bio-industry bases (February 2008)
Harbin Base
     The characteristic biomedicine industry is one of the five pillar industries that Harbin has focused on fostering. In addition, it has resource advantages. Harbin is a national key grain and bean production area and an important green food base. Harbin’s jurisdiction and surrounding areas are rich in biological resources, and the development of agricultural products, especially green food and animal products, has great potential for in-depth development.
     Construction goal By 2010, the annual output value of the biological industry will reach 40 billion yuan, and the core area of ​​the biological industry base will account for more than 75% of the total output value.
Texas Base
     Features The city has gathered more than 300 biological enterprises of various types, including 102 biological enterprises above designated size, 8 with sales revenue of more than 1 billion yuan, and 38 with sales of more than 100 million yuan.
     In 2007, the biological industry achieved an output value of 22 billion yuan, of which the biological manufacturing industry reached 16 billion yuan, accounting for 73% of the total biological industry output value. The production capacity of xylo-oligosaccharides is the first in the world, the production capacity of xylitol is the second in the world, and the production capacity of oligosaccharides is the first in Asia, with a comprehensive production capacity of 500,000 tons, accounting for 70% of the national production capacity. Has now formed the country's largest soybean high-protein production base.
     Construction goals: By 2010, the annual output value of the biological industry will reach 50 billion yuan; by 2020, the added value of the city's biological industry will exceed 120 billion yuan.
Taizhou Base
     The characteristics have initially formed an industrial system with biomedicine as the core and auxiliary development of bioenergy and biopesticide. In 2007, the sales of the biological industry was 25.6 billion yuan, of which the sales of the biomedical industry was 18 billion yuan, accounting for 70.3%. The total economic volume of the city's biomedical industry has been for 5 consecutive years, and its economic efficiency has ranked first in Jiangsu Province for 9 consecutive years. Leading enterprises such as Yangtze River, Suzhong, Jichuan, Jiangshan, etc. have all ranked among the top 100 in the national pharmaceutical industry.
     Construction goal: By 2010, the annual output value of the biomedical industry of the base will be 55 billion yuan; by 2015, the production and sales of the biomedical industry will increase by 20% annually.
Zhengzhou Base
     Characteristics Zhengzhou has outstanding characteristics of biological agriculture. The R&D level, industrial scale, and product market share are all in a leading position in the country, making important contributions to ensuring national food security. In 2007, the sales revenue of the biological industry exceeded 20 billion yuan, with an average annual growth rate of 41.1%.
     Construction goals: By 2010, the annual output value of the biological industry will reach 45 billion yuan, and the added value will reach over 13 billion yuan; by 2015, the annual output value of the biological industry will reach 150 billion yuan.
Tonghua Base
     Characteristic construction of 9 industrial parks and two logistics centers in 3 functional areas including core area, expansion area and radiation area. In 2007, Tonghua's pharmaceutical industry achieved an output value of 20.2 billion yuan, accounting for 27.2% of the city's GDP and 37.4% of the pharmaceutical industry in Jilin Province.
     The goal of building. By 2010, the modern Chinese medicine industry will realize an added value of 18.5 billion yuan; by 2015, the modern Chinese medicine industry will realize an added value of 37.5 billion yuan.
Nanning Base
     Focus on the development of non-food and bio-energy industries. Based on the existing industrial distribution of Nanning and considering the development potential and direction of the biological industry, the development direction of the high-tech industrial clusters in Nanning is preliminarily drawn up, namely, the establishment of bio-energy industry sub-bases, bio-pharmaceutical industry sub-bases, bio-manufacturing industry sub-bases, and bio-agriculture Four specialized biological industry sub-bases including industrial sub-bases.
     Construction goal: By 2010, the annual output value of the bio-industry will reach 69 billion yuan, of which the annual output value of bio-energy will account for 25 billion yuan in the annual output value of the bio-industry; by 2020, the annual output value of the bio-industry will reach about 153 billion yuan. The output value accounts for more than 38% of the annual output value of the biological industry, reaching 58 billion yuan.
Xi'an Base
     Features Xi'an High-tech Industrial Development Zone focuses on the development of biological medicine, and Yangling focuses on the development of biological agriculture.
     Construction goal By 2010, the annual output value of the biological industry will reach 60 billion yuan, with an added value of 20 billion yuan, accounting for 3% of the province’s GOP.
Tianjin Base
     Characteristic Efforts to build an export-oriented, modern biomedicine as the main body, the rapid development of bio-industry and bio-agriculture, and build a domestic first-class and world-important modern bio-industry manufacturing base integrating R&D, production, sales and service And key technology research and development transformation base. In 2006, the city's biological industry output value was nearly 30 billion yuan.
     Construction goal In 2010, the annual output value of the biological industry will reach 60 billion yuan.
Nanchang Base
     Features In 2007, the city's bio-industry assets totaled 45 billion yuan, main business income was 42 billion yuan, industrial added value was 14 billion yuan, profits and taxes were 7.8 billion yuan, and there were more than 80 bio-high-tech enterprises. In 2007, the export value of the city's biological industry was 410 million US dollars.
     Construction goal By 2010, the annual output value of the biological industry will reach 73 billion yuan.
Hangzhou Base
     Features have been formed with biotechnology drugs as the core and modern Chinese medicine as the basis